CPI inflation, retail sales, Jerome Powell congressional testimony, along with earnings from Coca-Cola, McDonald’s, Cisco, ...
The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...
Zacks.com on MSN3d
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product SalesVertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...
Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...
Markets were flat but positive in an initial trading day for a new week, basically shrugging off whatever warnings signs may have been considered regarding President Trump’s 25% steel tariff headline ...
Malay Mail on MSN8d
AI takes over: Singapore’s new property agent isn’t humanHome buyers in Singapore may soon rely on artificial intelligence rather than human agents to find their next property. Yesterday, property portal ...
On Feb. 24, from west to east, you can see Mercury, Saturn, Neptune, Venus, Uranus, Jupiter and Mars, all spanning 117.5°, ...
The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...
Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...
EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...
As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback